Short answer: Hormone therapy has not been shown to directly improve cognition in randomized trials. Started near the final menstrual period it is cognitively neutral and safe; started more than a decade later, older oral regimens increased dementia risk. Where it does help fog is indirectly, by removing night sweats and restoring sleep.
The three trials that matter
KEEPS randomized 693 recently menopausal women to oral conjugated estrogens, transdermal estradiol, or placebo for four years and found no difference in global cognition — no benefit, and importantly no harm.
ELITE tested the timing hypothesis directly by stratifying women by years since menopause. Cognitive outcomes were unchanged in both strata, while the cardiovascular endpoint favoured early initiation.
WHIMS, the source of most public fear, studied women aged 65 and over starting oral conjugated estrogens with medroxyprogesterone acetate. Dementia risk increased. That population, route, and formulation are not what a 50-year-old is offered today.
What this means in practice
- If you have vasomotor symptoms and fog, treating the vasomotor symptoms — with hormones or without — is the rational move.
- If you have fog and no other symptoms, hormone therapy is a weak indication and we will say so.
- Transdermal estradiol avoids the first-pass thrombotic risk of oral routes and is our default when hormones are appropriate.
- Early surgical menopause is a different case: hormone therapy until the average age of natural menopause is standard of care.
Want a plan rather than another supplement? A Kindr clinician will review your labs, sleep, mood, and vasomotor symptoms together and treat the drivers.
Start your visit →Not ready? Ask Dot, our free AI menopause companion.
Frequently asked questions
Is there a cognitive window of opportunity?
The timing hypothesis is best supported for cardiovascular outcomes. For cognition, the fair summary is neutrality with early initiation and risk with late initiation of older oral regimens.
Does the type of progestogen matter?
Micronized progesterone is generally preferred over medroxyprogesterone acetate on breast and possibly cognitive grounds, and it improves sleep for many women.
The brain fog hub
Mechanism, treatment evidence, the memory differential, sleep, and the workplace — one connected topic.
Other Kindr symptom hubs
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- Brain fog & menopauseJournal
- Sleep & menopauseJournal
- Is HRT safe?Journal
- Semax — cognitive peptidePeptide
- DSIP — delta sleep peptidePeptide
- When to start HRTJournal
Sources
- Greendale GA et al. Effects of the menopause transition and hormone use on cognitive performance (SWAN). Neurology 2009.
- Gleason CE et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: KEEPS-Cog. PLoS Med 2015.
- Henderson VW et al. Cognitive effects of estradiol after menopause: ELITE-Cog. Neurology 2016.
- Shumaker SA et al. Estrogen plus progestin and the incidence of dementia (WHIMS). JAMA 2003.
- Mosconi L et al. Perimenopause and emergence of an Alzheimer bioenergetic phenotype. PLoS One 2017.
- Guthrie KA et al. Effects of pharmacologic and nonpharmacologic interventions on insomnia symptoms (MsFLASH pooled). Sleep 2017.
- The Menopause Society. 2022 Hormone Therapy Position Statement.
Educational content only — not a substitute for professional medical advice, diagnosis, or treatment. The severity quiz is a screening aid, not a diagnosis. Reviewed by the Kindr Health clinical team · Last reviewed 2026-07-26.